|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|USRE44186||ASTRAZENECA AB||Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method|| |
(a month ago)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7951400||ASTRAZENECA AB||Coated tablet formulation and method|| |
(5 years from now)
Onglyza is owned by Astrazeneca Ab.
Onglyza contains Saxagliptin Hydrochloride.
Onglyza has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Onglyza are:
Onglyza was authorised for market use on 31 July, 2009.
Onglyza is available in tablet;oral dosage forms.
Onglyza can be used as method for treating type ii diabetes by administering saxagliptin; method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.
The generics of Onglyza are possible to be released after 30 November, 2028.
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic